Articles Vol. 62 No. 4 (2021) 21/06/2021

EFFECTS OF TRASTUZUMAB ON MYOCARDIAL FUNCTION ON BREAST CANCER PATIENTS

Bui Dang Minh Tri1, Le Cong Duy Anh2, Do Van Mai2, Nguyen Huu Phuc2, Nguyen Thi Thuy Linh
1 University of Medicine Pham Ngoc Thach
2 Tay Do University
Corresponding author: drtribui1@gmail.com
DOI: 10.52163/yhc.v62i4 (2021).107
20 Views
8 Downloads
Keywords
Breast cancer, myocardial function, Trastuzumab
Abstract

Objective: To investigate the effect of Trastuzumab on myocardial function on breast cancer patients at Thong Nhat hospital. Subjects and methods: a retrospective study on 48 patients with breast cancer treated with Trastuzumab at Thong Nhat hospital. Results: Percentage of patients with heart failure according to the Frammingham diagnostic criteria was 4.17%. The proportion of patients with no symptoms of heart failure according to Frammingham diagnostic criteria was 95.83%. According to the degree of EF change, the proportion of patients with decreased EF > 10% after treatment was 43.75%. With 9 patients with EF < 53%, accounting for 18.75%. The proportion of patients who had to discontinue therapy due to cardiotoxicity during treatment with Trastuzumab was 12.5%, with 6.25% stopping completely and 6.25% of patients stopping temporarily. Conclusion: the rate of patients with heart failure was little, the proportion of EF <53% was low. The proportion of patients who had to discontinue therapy due to cardiotoxicity during treatment with Trastuzumab was low.

References
[1]
Balduzzi S, Mantarro S, Guarneri V et al. Trastuzumab-containing regimens for metastatic breast cancer, Cochrane Database Syst Rev, 2014; 6: CD006242. Google Scholar
[2]
Joanna H, Leś D, Sarzyczny SD et al. Cardiac side effects of trastuzumab in breast cancer patients - single centere experiences, Contemporary oncology, 2013; 17(2): 190–195. Google Scholar
[3]
Seidman A, Hudis C, Pierri MK et al., Cardiac dysfunction in the trastuzumab clinical trials experience, J Clin Oncol, 2002; 20(5): 1215-21. Google Scholar
[4]
Somaira N, Aziz K, Park JY et al., Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction, J Am Heart Assoc., 2018; 7(15): e008637. Google Scholar
[5]
Serrano C, Cortés J, De Mattos AL et al., Trastuzumab – related cardiotoxicity in the elderly: a role for cardiovascular risk factors, Ann Oncol., 2012; 23: 897-902. Google Scholar
[6]
Tan-Chiu E, Yothers G, Romond E et al., Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31, J Clin Oncol., 2005; 23(31) :7811-7820. Google Scholar